Targeting Progress: Patient Perspective on Antibody-Drug Conjugates in Gynecologic Cancer Care
Release Date: 04/24/2025
Bridging the Gap: Enhancing Cancer Care Through Financial Navigation
CANCER BUZZ
The high cost associated with cancer diagnosis, treatment, and survivorship makes the burden of financial toxicity an unavoidable reality for many patients—and makes financial navigators central to the delivery of high-quality cancer care. In this vodcast episode, CANCER BUZZ speaks with Heather Simpson, BCPA, patient financial navigator lead, who shares her experience using the ACCC Financial Advocacy Network’s financial advocacy services guidelines assessment tool to pinpoint financial navigation challenges within her cancer program. Heather Simpson, BCPA Patient Financial Navigator...
info_outline
Managing CDK4/6 Inhibitor Toxicities in Breast Cancer
CANCER BUZZ
Effective management of adverse events and addressing barriers to care are critical to optimizing outcomes and maintaining quality of life for patients receiving CDK4/6 inhibitors. In this episode, CANCER BUZZ speaks with Julia Lea Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator in solid tumor oncology at Atrium Health Levine Cancer Institute about proactive, team-based strategies to identify, monitor, and manage treatment-related toxicities in patients with early-stage and metastatic HR-positive, HER2-negative breast cancer. Dr. Ziegengeist sheds light on the patient journey, the...
info_outline
Increasing Access and Representation in Clinical Trials
CANCER BUZZ
Clinical trials are vital to offering and developing the most effective treatment options. However, there are large disparities in enrollment across race, ethnicity, geography, and type of cancer care center. Mary Bird Perkins Cancer Center in Baton Rouge, LA uses local partnerships, culturally tailored outreach, and workforce innovation to drive sustainable and equitable participation in clinical trials. Minorities now make up 21% of their clinical trial participation, surpassing the national average. Following these meaningful gains in attracting local minority populations and underserved...
info_outline
Stay Ahead of the Curve on CDK4/6 Inhibitor Toxicities
CANCER BUZZ
Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related adverse events in patients with early-stage and metastatic breast cancer receiving CDK4/6 inhibitors. She discusses the importance of individualized care and robust patient education around lifestyle...
info_outline
Transforming Cancer Detection and Treatment
CANCER BUZZ
In this episode, CANCER BUZZ speaks with Bart Daugherty, vice president of clinical technology and systems at Georgetown Cancer Center, Lifepoint Health, about his program’s receipt of a 2025 ACCC Innovator Award. Lifepoint’s innovation, Transforming Cancer Detection and Treatment with the AI-Driven Healthy Person Program, leverages artificial intelligence (AI) to analyze the health records of all patients who have received care at Lifepoint Health’s facilities and identify those who are at risk of developing catastrophic diseases. This initiative, dubbed the Healthy Person Program, has...
info_outline
Adopting Machine Learning-Enabled Decision Support to Improve Oncology End-of-Life Outcomes
CANCER BUZZ
In this episode, CANCER BUZZ speaks with Andrew Munchel, MSN, RN, OCN, CPHQ, quality program administrator, oncology service line at WellSpan Health, WellSpan Cancer Institute about his program’s receipt of a 2025 ACCC Innovator Award. WellSpan Cancer Institute’s innovation, Adopting Machine Learning-Enabled Decision Support to Improve Oncology End-of-Life Outcomes, involved the implementation of the End-of-Life Care Index, a machine learning and cognitive computing model that predicts 12-month mortality risk, into the cancer program’s clinical decision support tool. Driven by a desire...
info_outline
Ambulatory Care Excellence (ACE): Charting a New Path in Ambulatory Care Model and Coordination
CANCER BUZZ
In this episode, CANCER BUZZ speaks with Anna Liza Rodriguez, MSN, MHA, RN, OCN, NEA-BC, chief nursing officer and vice president of Nursing and Patient Care Services at Fox Chase Cancer Center about her program’s receipt of a 2025 ACCC Innovator Award. Fox Chase Cancer Center’s innovation, Ambulatory Care Excellence (ACE): Charting a New Path in Ambulatory Care Model and Coordination, is a structured approach designed to improve efficiency, coordination, and patient outcomes in ambulatory cancer care while ensuring top of license scope of work for clinicians. Rodriguez will discuss key...
info_outline
Optimizing Germline and Somatic Testing in Prostate Cancer
CANCER BUZZ
Genetic factors play a critical role in prostate cancer treatment planning, with both germline and somatic mutations guiding therapeutic decisions. The Association of Cancer Care Centers (ACCC) remains committed to improving prostate cancer care and has developed the Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing. In this episode, CANCER BUZZ speaks with Andrea Murphy, FNP-C, ACGN, CGRA, genetics nurse practitioner at Mary Bird Perkins Cancer Center and Amy D. Smith, FNP-BC, director at Meredith & Jeannie Ray Cancer Center, about the...
info_outline
Better Bladder Cancer Care, Closer to Home
CANCER BUZZ
Navigating the growing complexity of bladder cancer care is essential to improving patient access and treatment closer to home. In this episode, CANCER BUZZ speaks with Suzanne Merrill, MD, urologic oncologist at Colorado Urology about barriers and solutions to delivering high-quality bladder cancer care in community settings. CANCER BUZZ also speaks with Patrick Hensley, MD, urologist at University of Kentucky Markey Cancer Center, about implementing the Delivering High-Quality Bladder Cancer Care infographic in the community setting. Created by ACCC and BCAN, the infographic describes the...
info_outline
ASCO E-Poster: Immune-Related Adverse Events
CANCER BUZZ
Immune-related adverse events (AEs) are becoming more frequent in oncology patients receiving immunotherapy. To better understand emerging trends and education needs, the Association of Cancer Care Centers (ACCC) developed the Immuno-Oncology Census as part of its ongoing commitment to sharing up-to-date strategies for managing adverse events. In this episode, CANCER BUZZ speaks with Bat-ami Gordon, clinical research PhD candidate at the Icahn School of Medicine at Mount Sinai, who discusses best practices for cancer care providers to identify immune-related AEs caused by immunotherapy. ...
info_outlineAntibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient’s perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx.
“[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I’m not just a number, I’m a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett
Nancy Mallett
Patient Advocate
Resources:
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD
Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP
ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8
Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962
Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ
Funder Statement
This program is supported by AbbVie.